natgillin/translations-raw huggingface dataset:
• a hole in your gut wall,
• u slučaju napuknuća u stijenci crijeva,
No clinically relevant interaction of co-administered chemotherapy on bevacizumab pharmacokinetics was observed based on the results of population pharmacokinetic analyses.
Rezultati analiza populacijske farmakokinetike pokazali su da nema klinički značajnih interakcija istodobno primijenjene kemoterapije na farmakokinetiku bevacizumaba.
However, sleepiness and fainting have been reported with MVASI use.
Međutim, pri primjeni lijeka MVASI prijavljene su pospanost i nesvjestica.
Hazard ratio
Omjer rizika
Rate
Stopa
N Response rate
Razlika u stopama odgovora
• blockage in the gut or bowel,
• zastoj rada crijeva,
Asthenia, Fatigue, Pyrexia, Pain,
Opći poremećaji i reakcije na mjestu primjene astenija, umor, pireksija, bol, upala sluznice letargija
No increase in the incidence of other reactions, including gastrointestinal perforation, wound healing complications, congestive heart failure, and haemorrhage was observed in elderly patients (> 65 years) receiving bevacizumab as compared to those aged ≤ 65 years treated with bevacizumab.
U starijih bolesnika (> 65 godina) koji su primali bevacizumab, u odnosu na bolesnike u dobi od ≤ 65 godina liječene bevacizumabom, nije primijećen porast incidencije drugih reakcija, uključujući gastrointestinalne perforacije, komplikacije pri zacjeljivanju rana, kongestivno zatajenje srca i krvarenje.
Endpoint (months)
percentil (mjeseci)
Increased rates of severe neutropenia, febrile neutropenia, or infection with or without severe neutropenia (including some fatalities) have been observed in patients treated with some myelotoxic chemotherapy regimens plus bevacizumab in comparison to chemotherapy alone.
U bolesnika liječenih nekim mijelotoksičnim kemoterapijskim protokolima u kombinaciji s bevacizumabom su, u usporedbi s primjenom samo kemoterapije, opažene povećane stope teške neutropenije, febrilne neutropenije te infekcije praćene teškom neutropenijom ili bez nje (s nekoliko smrtnih ishoda).
Posterior reversible encephalopath y syndromea,b,c, Hypertensive encephalopath yc
Poremećaji reproduktivnog sustava i dojki zatajivanje jajnikab,c,d bol u zdjelici
Capecitabine oral bid for 2 weeks (followed by 1 week off treatment)
1000 mg/m2 peroralno dva puta na dan kapecitabin, peroralno, dva puta na dan tijekom 2 tjedna (slijedi jednotjedni prekid)
Median PFS (months) Hazard ratio (95% CI)4 Randomised patients with stage IV disease CPP (n = 153)
Randomizirane bolesnice sa stadijem IV bolesti CPP (n = 153)
Haemorrhagea,b, Thromboembolis m (venous)a,b,
Krvožilni poremećaji hipertenzijaa,b tromboembolija (arterijska)a,b, krvarenjea,b, tromboembolija (venska)a,b, duboka venska tromboza bubrežna trombotska mikroangiopatijab,c aneurizme i disekcije arterije
A large phase III trial was designed to investigate the treatment effect of bevacizumab in combination with paclitaxel, as measured by the primary endpoint of PFS. A clinically meaningful and statistically significant improvement in PFS was observed.
Djelotvornost liječenja bevacizumabom u kombinaciji s paklitakselom ispitana je u velikom ispitivanju faze III, u kojima je primarna mjera ishoda bilo preživljenje bez progresije bolesti.
Caution should be taken when treating these patients with MVASI.
Kad se takvi bolesnici liječe lijekom MVASI, potreban je oprez.
These patients often do not have other treatment options.
Ti bolesnici često nemaju druge mogućnosti liječenja.
Treatment is continued for 6 weeks, but may be extended for up to another 6 weeks if needed.
Liječenje traje šest tjedana, a prema potrebi može se produžiti najviše još šest tjedana.
The recommended dose is one tablet twice a day.
Preporučena je doza jedna tableta dvaput dnevno.
Tablets must not be chewed or swallowed whole.
Tablete se ne smiju žvakati niti cijele progutati.
Jorveza budesonide
Jorveza budezonid
What measures are being taken to ensure the safe and effective use of Jorveza?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Jorveza?
After 6 weeks, around 58% of the patients taking Jorveza (34 out of 59 patients) had reduced eosinophils and no symptoms or only minimal symptoms, whereas none of the 29 patients taking placebo had these effects.
Nakon šest tjedana oko 58 % bolesnika koji su primali lijek Jorveza (34 od 59 bolesnika) imalo je niže koncentracije eozinofila te nije imalo nikakvih simptoma ili su simptomi bili vrlo blagi, dok ni kod jednog od 29 bolesnika koji su primali placebo nisu zabilježeni takvi učinci.
What is Jorveza and what is it used for?
Što je Jorveza i za što se koristi?
The tablet is placed on the tongue and pressed against the roof of the mouth for around two minutes until it dissolves.
Tableta se stavi na jezik, pritisne o nepce i tako drži oko dvije minute sve dok se potpuno ne otopi.
The European Medicines Agency decided that Jorveza's benefits are greater than its risks and recommended that it be approved for use in the EU.
Europska agencija za lijekove zaključila je da koristi od lijeka Jorveza nadmašuju s njim povezane rizike te je preporučila davanje odobrenja za njegovu primjenu u EU-u.
This is a summary of the European public assessment report (EPAR) for Jorveza.
Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Jorveza.
Other information about Jorveza
Ostale informacije o lijeku Jorveza
It is not intended to provide practical advice on how to use Jorveza.
Svrha sažetka nije davati praktične savjete o primjeni lijeka Jorveza.
The full EPAR for Jorveza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjeloviti EPAR za lijek Jorveza nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What are the risks associated with Jorveza?
Koji su rizici povezani s lijekom Jorveza?
Side effects with Jorveza are mainly the same as those of other similar medicines.
Nuspojave lijeka Jorveza uglavnom su iste kao i nuspojave drugih sličnih lijekova.
Jorveza is available as orodispersible tablets (1 mg).
Lijek Jorveza dostupan je u obliku raspadljivih tableta za usta (1 mg).
Why is Jorveza approved?
Zašto je lijek Jorveza odobren?
The summary of the opinion of the Committee for Orphan Medicinal Products for Jorveza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Sažetak mišljenja Odbora za lijekove za rijetke bolesti o lijeku Jorveza nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Jorveza have been included in the summary of product characteristics and the package leaflet.
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Jorveza nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
Because the number of patients with eosinophilic oesophagitis is low, the disease is considered ‘rare', and Jorveza was designated an ‘orphan medicine' (a medicine used in rare diseases) on 5 August
Budući da je broj bolesnika s eozinofilnim ezofagitisom nizak, bolest se smatra „rijetkom” te je lijek Jorveza dobio status „lijeka za liječenje rijetkih bolesti” 5. kolovoza 2013.
Corticosteroids help reduce inflammation by attaching to receptors of immune cells and reducing the release of substances that are involved in the inflammation process.
Kortikosteroidi pomažu pri ublažavanju upale vezivanjem na receptore imunosnih stanica te na taj način smanjuju oslobađanje tvari koje sudjeluju u upalnom procesu.
The most common side effects with Jorveza (which may affect up to 3 in 10 people) are fungal infections in the mouth, pharynx (throat) and oesophagus.
Najčešće su nuspojave lijeka Jorveza (koje se mogu javiti u do 3 na 10 osoba) gljivične infekcije u ustima, grlu (ždrijelu) ili jednjaku.
The active substance in Jorveza, budesonide, is a corticosteroid medicine.
Djelatna tvar lijeka Jorveza je budezonid, kortikosteroidni lijek.
For more information about treatment with Jorveza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Više informacija o liječenju lijekom Jorveza pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
The main measure of effectiveness was the level of eosinophils in the oesophagus and improvement in symptoms.
Glavna mjera učinkovitosti bila je koncentracije eozinofila u jednjaku i stupanj ublažavanja simptoma.
Jorveza was compared with placebo (a dummy treatment).
Lijek Jorveza uspoređen je s placebom (prividnim liječenjem).
It is caused by a large build-up of white blood cells called eosinophils in the lining of the oesophagus.
Uzrokovan je stvaranjem velikog broja bijelih krvnih stanica, tj. eozinofila, u stijenci jednjaka.
Jorveza was shown to be effective in one main study involving 88 adults with eosinophilic oesophagitis.
Lijek Jorveza pokazao se učinkovitim u jednom glavnom ispitivanju kojim je bilo obuhvaćeno 88 odraslih bolesnika s eozinofilnim ezofagitisom.
For practical information about using Jorveza, patients should read the package leaflet or contact their doctor or pharmacist.
Praktične informacije o primjeni lijeka Jorveza bolesnici trebaju pročitati u uputi o lijeku, odnosno trebaju se obratiti svojem liječniku ili ljekarniku.
For the full list of all side effects and restrictions with Jorveza, see the package leaflet.
Potpuni popis svih nuspojava i ograničenja prilikom primjene lijeka Jorveza potražite u uputi o lijeku.
Jorveza benefits patients with eosinophilic oesophagitis by improving the symptoms of the disease and reducing the excess of eosinophils.
Jorveza koristi bolesnicima s eozinofilnim ezofagitisom jer ublažava simptome bolesti i snižava prekomjerne razine eozinofila.
Jorveza can only be obtained with a prescription and treatment should be started by a doctor experienced with diagnosing and treating eosinophilic oesophagitis.
Jorveza se izdaje samo na liječnički recept, a liječenje treba započeti liječnik s iskustvom u dijagnosticiranju i liječenju eozinofilnog ezofagitisa.
How is Jorveza used?
Kako se Jorveza koristi?
How does Jorveza work?
Kako djeluje Jorveza?
What benefits of Jorveza have been shown in studies?
Koje su koristi lijeka Jorveza utvrđene u ispitivanjima?
Jorveza contains the active substance budesonide.
Jorveza sadržava djelatnu tvar budezonid.
Jorveza is a medicine used to treat adults with eosinophilic oesophagitis.
Jorveza je lijek koji se koristi za liječenje odraslih osoba oboljelih od eozinofilnog ezofagitisa.
During this time the patient should steadily swallow the saliva with the dissolved medicine.
Dok se tableta raspada, bolesnik treba pomalo gutati slinu s otopljenim lijekom.
Eosinophilic oesophagitis is inflammation of the oesophagus (the food-pipe that leads from the mouth to the stomach), which causes symptoms including dysphagia (difficulty swallowing) and obstruction of the oesophagus.
Eozinofilni ezofagitis je upala jednjaka (ezofagusa) koja uzrokuje simptome poput disfagije (otežanog gutanja) i začepljenje jednjaka.
After Jorveza dissolves in the mouth, the saliva carries it to the oesophagus where it reduces the inflammation and relieves the symptoms of eosinophilic oesophagitis.
Nakon što se lijek Jorveza otopi u ustima, slinom se prenosi u jednjak te ublažava upalu i simptome eozinofilnog ezofagitisa.
50000 IU Powder and solvent for solution for injection
NeoRecormon 50000 IU Prašak i otapalo za otopinu za injekciju
Subcutaneous or intravenous use powder: multidose vial (glass); solvent: ampoule (glass)
Za primjenu potkožno ili u venu prašak: višedozna bočica (staklo); otapalo: ampula (staklo)
1 vial + 1 ampoule
1 bočica + 1
solvent: 10 ml (reconst.
otapalo: 10 ml (rekonst. otopina 5000 IU/ml)
MYLAN SAS 117, allée des Parcs 69800 Saint-Priest France
Francuska MYLAN SAS 117, allée des Parcs 69800 Saint-Priest France
Oficina D 28230 Las Rozas (Madrid) Spain
28230 Las Rozas (Madrid) Spain
Germany Hexal Aktiengesellschaft Industriestr.
Njemačka Hexal Aktiengesellschaft Industriestr.
Desitin Arzneimittel GmbH Postfach 630164
Norveška Desitin Arzneimittel GmbH Postfach 630164
ARENA GROUP S.A. Str. Ştefan Mihăileanu nr.
Rumunjska S.C. ARENA GROUP S.A. Str. Ştefan Mihăileanu nr.
Luxembourg Hexal AG Industriestrasse 25 83067 Holzkirchen Germany
Luksemburg Hexal AG Industriestrasse 25 83067 Holzkirchen Germany
Germany IIP - Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH
Njemačka IIP - Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH
Luxembourg Eurogenerics SA Esplanade Heysel b22
Luksemburg Eurogenerics SA Esplanade Heysel b22
PSC 170 00 Holesovice Czech Republic
PSC 170 00 Holesovice Czech Republic magnezijev valproat
Kampenringweg 45 D-E 2803 PE GOUDA The Netherlands
Kampenringweg 45 D-E 2803 PE GOUDA
110, Esplanade du Général de Gaulle
Francuska TEVA SANTE 110, Esplanade du Général de Gaulle
Arrow Generiques 26, avenue Tony Garnier 69007 Lyon
Francuska Arrow Generiques 26, avenue Tony Garnier 69007 Lyon
Laboratoire AGUETTANT 1, rue Alexander Fleming 69007 Lyon
Francuska Laboratoire AGUETTANT 1, rue Alexander Fleming 69007 Lyon
SANOFI AVENTIS, S.A. Josep Plá, 2
Španjolska SANOFI AVENTIS, S.A. Josep Plá, 2
Austria sanofi-aventis GmbH SATURN Tower, Vienna DC Leonard-Bernstein-Straße
Austrija sanofi-aventis GmbH SATURN Tower, Vienna DC Leonard-Bernstein-Straße
Latvia sanofi-aventis Latvia SIA Kr.Valdemara 33-8 Riga LV1010
Latvija sanofi-aventis Latvia SIA Kr.Valdemara 33-8 Riga LV1010
Luxembourg Takeda Belgium Chaussée de Gand 615 1080 Bruxelles
Luksemburg Takeda Belgium Chaussée de Gand 615 1080 Bruxelles
Luxembourg Mylan BVBA/SPRL Terhulpsesteenweg 6 box A 1560 Hoeilaart
Luksemburg Mylan BVBA/SPRL Terhulpsesteenweg 6 box A 1560 Hoeilaart
Evropská 846/176a 160 00 Prague 6
Sanofi-Aventis, s.r.o. Evropská 846/176a 160 00 Prague 6
Germany 1 A Pharma GmbH Keltenring 1 + 3
Njemačka 1 A Pharma GmbH Keltenring 1 + 3
Ranbaxy Pharmacie Génériques
Francuska Ranbaxy Pharmacie Génériques
Luxembourg Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem
Luksemburg Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem
D-22311 HAMBURG Deutschland
D-22311 HAMBURG
Sanofi-Aventis Netherlands B.V.
Nizozemska Sanofi-Aventis Netherlands B.V.
Germany Sanofi-Aventis Deutschland GmbH
Njemačka Sanofi-Aventis Deutschland GmbH
Convulsofin Tabletten
Convulsofin Tabletten tablet
Denmark Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark
Edvard Thomsens Vej 14 DK-2300 København
Germany Stadapharm GmbH Stadastr 2-18
Njemačka Stadapharm GmbH Stadastr 2-18
Germany Mylan dura GmbH Wittichstr.
Njemačka Mylan dura GmbH Wittichstr.
Sanofi-Aventis Bulgaria EOOD
Bugarska Sanofi-Aventis Bulgaria EOOD
Depakine sirop
Depakine sirup
Via Scarlatti Domenico, 31 20124 Milano Italy
Via Scarlatti Domenico, 31 20124 Milano Italy valproatna kiselina, natrijev valproat
Sanofi-Aventis zrt.
Mađarska Sanofi-Aventis zrt.
Germany Dolorgiet GmbH & Co.KG Otto-von-Guericke-Str. 1
Njemačka Dolorgiet GmbH & Co.KG Otto-von-Guericke-Str.
Orlept (SF) Liquid or Sodium Valproate 40mg/ml oral solution
Orlept (SF) Liquid or Sodium Valproate 40mg/ml oral solution oralna otopina
Depakine vloeistof voor kinderen, vloeistof voor oraal gebruik 300 mg/ml
Depakine vloeistof voor kinderen, vloeistof voor oraal gebruik 300 mg/ml oralna tekućina
Syrup
sirup
Germany Orion Corporation Orionintie 1 A
Njemačka Orion Corporation Orionintie 1 A
500-1000 mg Modified-release granules
500-1000 mg granule s prilagođenim oslobađanjem
Germany ALIUD PHARMA GmbH Gottlieb-Daimler-Str. 19
Njemačka ALIUD PHARMA GmbH Gottlieb-Daimler-Str. 19
LT-09310 Vilnius
Juozapavičiaus g. 6/2 LT-09310 Vilnius Lithuania
Valproinsäure- ratiopharm Lösung
Valproinsäure- ratiopharm Lösung oralna otopina
Germany Neuraxpharm Arzneimittel GmbH
Njemačka Neuraxpharm Arzneimittel GmbH
DEMO ABEE 21st Km Athens-Lamias National Highway 14568 Kryoneri Greece
National Highway 14568 Kryoneri Greece
Depakine suikervrije stroop, drank 200 mg/5 ml
Depakine suikervrije stroop, drank 200 mg/5 ml oralna otopina
Sanofi-Aventis Croatia d.o.o.
Hrvatska Sanofi-Aventis Croatia d.o.o.
Romania Sanofi-Aventis France 1-13 Boulevard Romain Rolland
Rumunjska Sanofi-Aventis France 1-13 Boulevard Romain Rolland
LABORATOIRES ALTER 3, avenue de la Baltique, ZI de Courtaboeuf 91140 Villebon Sur Yvette France
Francuska LABORATOIRES ALTER 3, avenue de la Baltique, ZI de Courtaboeuf
DEPAKINE 57,64 mg/ml, sirop 57.64 mg
DEPAKINE 57,64 mg/ml, sirop 57,64 mg sirup
Valpro TAD Lösung
Valpro TAD Lösung oralna otopina
17 Bonifraterska Str. 00-203 Warsaw Poland
Sanofi-Aventis Sp. z o.o. 17 Bonifraterska Str. 00-203 Warsaw Poland
Germany Winthrop Arzneimittel GmbH
Njemačka Winthrop Arzneimittel GmbH
Germany betapharm Arzneimittel GmbH
Njemačka betapharm Arzneimittel GmbH
Epilim 100mg Crushable Tablet
Epilim 100mg Crushable Tablet tableta
1000 Ľubľana Slovenia
1000 Ljubljana
Epilim 100 mg Crushable Tablets
Epilim 100 mg Crushable Tablets tableta
VALPROATE DE SODIUM AGUETTANT 400 mg/4 ml, solution injectable
VALPROATE DE SODIUM AGUETTANT 400 mg/4 ml, solution injectable otopina za injekciju u venu
Modified-release tablet
tableta s prilagođenim oslobađanjem
Depakine Chronosphere 250 166.76 mg 72.61 mg
Depakine Chronosphere 250 166,76 mg + 72,61 mg granule s produljenim oslobađanjem
Epilim 400mg Powder & solvent for solution for injection
Epilim 400mg Powder & solvent for solution for injection prašak za injekciju u venu
Sodium Valproate Oral solution BP 200mg/5ml
Sodium Valproate Oral solution BP 200mg/5ml oralna otopina
Depakine Chronosphere 750 500,06 mg 217,75 mg
Depakine Chronosphere 750 500,06 mg + 217,75 mg granule s produljenim oslobađanjem
Convulex 50 mg/ml syrup 50 mg/ml
Convulex 50 mg/ml syrup 50 mg/ml sirup
Depakine 57,64 mg/ml syrup 57.64 mg/ml
Depakine 57,64 mg/ml syrup 57,64 mg/ml sirup
Sodium valproate liquid 200mg/5ml
Sodium valproate liquid 200mg/5ml oralna otopina
Depakine Chronosphere 100 66,66 mg 29.03 mg
Depakine Chronosphere 100 66,66 mg + 29,03 mg granule s produljenim oslobađanjem
Depakine Enteric 150 mg 150 mg
Depakine Enteric 150 mg 150 mg tablet
Depakine Chronosphere 1000 666,60 mg 290.27 mg
Depakine Chronosphere 1000 666,60 mg + 290,27 mg granule s produljenim oslobađanjem
Depakine Chrono 500, tabletten met gereguleerde afgifte 500 mg
Depakine Chrono 500, tabletten met gereguleerde afgifte 500 mg tableta s prilagođenim oslobađanjem
Magnesium Valproate
Italy magnezijev valproat
Romania Desitin Arzneimittel Gmbh Weg beim Jaeger 214
Rumunjska Desitin Arzneimittel Gmbh Weg beim Jaeger 214
Natriumvalproaat Apotex 300 mg/5 ml, drank
Natriumvalproaat Apotex 300 mg/5 ml, drank oralna otopina
Convulex 100 mg/ml solution for injection/concentrate for solution for infusion
Convulex 100 mg/ml solution for injection/concentrate for solution for infusion otopina za injekciju/infuziju u venu
Depakine Chrono 300, tabletten met gereguleerde afgifte 300 mg
Depakine Chrono 300, tabletten met gereguleerde afgifte 300 mg tableta s prilagođenim oslobađanjem
Prolonged-release capsule
kapsula s produljenim oslobađanjem
Modified-release capsule, hard
kapsula s produljenim oslobađanjem, tvrda
13435 Berlin espa-valept 300 mg retard 199.8 mg, 87 mg
Germany espa-valept 300 mg retard 199,8 mg, 87 mg
Valpromide Depamide 300 mg comprimidos gastrorresistentes
Spain valpromid Depamide 300 mg comprimidos gastrorresistentes
Valproat HEXAL 300mg/ml Lösung
Valproat HEXAL 300mg/ml Lösung oralna otopina
Germany Desitin Arzneimittel Gmbh Weg beim Jaeger 214
Njemačka Desitin Arzneimittel Gmbh Weg beim Jaeger 214
DEPAKINE CHRONO (SPHERE) 1000 mg/sachet Coated granules in sachet
DEPAKINE CHRONO (SPHERE) 1000 mg/vrećica obložene granule u vrećici
Germany TAD Pharma GmbH Heinz-Lohmann-Str. 5
Njemačka TAD Pharma GmbH Heinz-Lohmann-Str.
Sodium valproate 100mg/ml solution for injection or infusion
Sodium valproate 100mg/ml solution for injection or infusion otopina za injekciju/infuziju u venu
Depakine Chronosphere 500 333.30 mg 145,14 mg
Depakine Chronosphere 500 333,30 mg + 145,14 mg granule s produljenim oslobađanjem
Depakine 300 mg/ml Tropfen 300 mg/ml
Depakine 300 mg/ml Tropfen 300 mg/ml oralna otopina
Valproic acid Convulex gelule gastro résistante
Convulex gelule gastro résistante želučanootporna kapsula
Episenta solution for injection 100 mg/ml
Episenta solution for injection 100 mg/ml otopina za injekciju u venu
Valpromide DEPAMIDE 300 mg, comprimé pelliculé gastro-résistant
France valpromid DEPAMIDE 300 mg, comprimé pelliculé gastro-résistant
Germany AbZ-Pharma GmbH Graf-Arco-Str. 3
Njemačka AbZ-Pharma GmbH Graf-Arco-Str.
Depakine 300 mg/5 ml
Depakine 300 mg/5 ml sirup
Orfiril CR 1000 mg, granulaat met gereguleerde afgifte
Orfiril CR 1000 mg, granulaat met gereguleerde afgifte granule s prilagođenim oslobađanjem
Convulex 300 mg/ml oral solution
Convulex 300 mg/ml oral solution oralna otopina
Depakine 100 mg/ml polvo y disolvente para solución inyectable
Depakine 100 mg/ml polvo y disolvente para solución inyectable prašak i otapalo za otopinu za injekciju u venu
Germany Ratiopharm GmbH Graf-Arco-Strasse 3
Njemačka Ratiopharm GmbH Graf-Arco-Strasse 3
Sanofi-Aventis SpA Viale Luigi Bodio, 37/B 20158 Milano Italy
Sanofi-Aventis SpA Viale Luigi Bodio, 37/B 20158 Milano Italy valpromid Depamide
Orfiril CR 500 mg, granulaat met gereguleerde afgifte
Orfiril CR 500 mg, granulaat met gereguleerde afgifte granule s prilagođenim oslobađanjem
EG LABO - Laboratoires EuroGenerics "Le Quintet" - bâtiment A 12, rue Danjou 92517 Boulogne Billancourt Cedex
92517 Boulogne Billancourt Cedex
VALPROATE DE SODIUM ARROW 200 mg/ml, solution buvable
VALPROATE DE SODIUM ARROW 200 mg/ml, solution buvable oralna otopina
Convulex 300 mg/ml - Lösung zum Einnehmen
Convulex 300 mg/ml - Lösung zum Einnehmen oralna otopina
Orfiril Injektionslösung
Orfiril Injektionslösung otopina za injekciju u venu
Depakine Enteric 300 mg 300 mg
Depakine Enteric 300 mg 300 mg tablet
VALPROATE DE SODIUM ZENTIVA 200 mg/ml, solution buvable
VALPROATE DE SODIUM ZENTIVA 200 mg/ml, solution buvable oralna otopina
Orfiril 100 mg/ml, oplossing voor injectie
Orfiril 100 mg/ml, oplossing voor injectie otopina za injekciju u venu
DEPAKINE CHRONO 300 mg filmom obložene tablete
DEPAKINE CHRONO 300 mg filmtabletta filmom obložena tableta
Episenta 150mg Prolongedrelease capsules
Episenta 150mg Prolongedrelease capsules kapsula s produljenim oslobađanjem
Prolonged-release capsule, hard
Orfiril long kapsula s produljenim oslobađanjem, tvrda
Solution for injection/concentra te for solution for infusion
otopina za injekciju/ koncentrat za otopinu za infuziju u venu
DEPAKINE CHRONO 500 mg filmom obložene tablete
DEPAKINE CHRONO 500 mg filmtabletta filmom obložena tableta
Convulex Tropflösung
Convulex Tropflösung oralna otopina
DEPAKINE 200 mg/ml, solution buvable
DEPAKINE 200 mg/ml, solution buvable oralna otopina
Episenta 300mg Prolongedrelease capsules
Episenta 300mg Prolongedrelease capsules kapsula s produljenim oslobađanjem
Valproic acid Convulex 50 mg/ml - Sirup für Kinder
Convulex 50 mg/ml - Sirup für Kinder sirup
Natriumvalproat G.L.
VALPROATE DE SODIUM GNR L.P.
Depakine 200 mg/ml solución oral
Depakine 200 mg/ml solución oral oralna otopina
13435 Berlin espa-valept 500 mg retard 333 mg, 145 mg
Germany espa-valept 500 mg retard 333 mg, 145 mg
Valproic acid CONVULEX 50 mg/ml szirup gyermekeknek
CONVULEX 50 mg/ml szirup gyermekeknek sirup
Germany TEVA GmbH Graf-Arco-Str. 3
Njemačka TEVA GmbH Graf-Arco-Str.
Valproic acid ORFIRIL SAFT
Orfiril Saft oralna otopina
Orfiril CR 300 mg, capsules met gereguleerde afgifte
Orfiril CR 300 mg, capsules met gereguleerde afgifte kapsula s prilagođenim oslobađanjem, tvrda
Orfiril CR 150 mg, capsules met gereguleerde afgifte
Orfiril CR 150 mg, capsules met gereguleerde afgifte kapsula s prilagođenim oslobađanjem, tvrda
Valproic acid DEPAKINE 50 mg/ml szirup 50 mg/ml
DEPAKINE 50 mg/ml szirup 50 mg/ml sirup
Valproát chrono Sandoz 500 mg tablety s predľženým uvoľňovaním
Valproát chrono Sandoz 500 mg tablety s predľženým uvoľňovaním tableta s prilagođenim oslobađanjem
Ireland Sanofi-aventis Ireland Ltd. T/A SANOFI
Sanofi-aventis Ireland Ltd.